Surbhi Sidana, MD

Dr. Jason Westin, a lymphoma expert at MD Anderson, and Dr. Surbhi Sidana, who leads Stanford's Myeloma CAR-T program, dive into the intricacies of CAR-T cell therapy. They discuss its powerful mechanism and its application in treating cancers. The conversation highlights acute side effects like cytokine release syndrome and neurotoxicity, alongside strategies for their management. Chronic side effects, including infection risks and monitoring practices, are also explored, providing vital insights for oncologists on patient care.

Experts Salomon Manier, Surbhi Sidana, and Hermann Einsele discuss the optimal sequencing of bispecific antibodies and CAR-T cells in multiple myeloma, highlighting data from recent clinical trials. They explore mechanisms of resistance, factors to consider when sequencing, and potential sequencing strategies, recommending CAR-T cell therapy followed by bispecific antibodies based on emerging data.